Epithelial Ovarian Cancer Drugs Market Overview:
Prostate cancer is cancer in which abnormal cells in the prostate gland proliferate and expand uncontrollably. Prostate cancer is males’ sixth-leading cause of death and the eleventh leading cause of death from any disease.
Ovarian cancer is a form of cancer that affects the female reproductive system’s ovaries. The most common kind of ovarian cancer is epithelial ovarian cancer. The majority of ovarian tumors (90 percent) are epithelial. Ovarian cancer that begins in the epithelial layer covering the ovary is known as epithelial ovarian cancer.
Epithelial Ovarian Cancer Drugs Market Size Growth Rate:
According to the research report published by the DataM Intelligence, the global epithelial ovarian cancer drugs market size was valued at USD billion in 2021, it is projected to reach USD billion by 2029, with growth at a CAGR of % over the forecast period 2022-2029.
In the pharmaceutical sector, companies are actively innovating and creating combination medications to treat ovarian cancer. Combination medications address complex medical diseases by combining two or more active pharmaceutical ingredients (APIs) into a single dosage form. Pharmaceutical businesses in the ovarian cancer medications market are investing in the research and development of new products, such as combination drugs, to lower manufacturing costs, enhance compliance and efficiency, improve medication concordance, raise profitability, and reduce adverse effects.
The global epithelial ovarian cancer drugs market is expected to grow due to rising cancer incidences, increased research and development activities, major market players currently developing drugs and chemotherapies to manage ovarian cancer, and growing government initiatives to raise awareness about the disease during the forecast period.
Ovarian cancer is the fifth most commonly occurring cancer in women and the 18th most commonly occurring cancer across the globe. According to a World Ovarian Cancer Coalition study, an estimated 55% rise is expected in the number of ovarian cancer patients by 2035. About 90 out of 100 tumors of the ovary (90%) are epithelial. According to the Cancer Statistics in 2020, published by the American Cancer Society, about 1,806,590 new cancer cases were diagnosed in 2021, and about 21,410 women will receive a new diagnosis of ovarian cancer.
The market may be hampered by a lack of awareness of the symptoms of ovarian cancer. Ovarian cancer symptoms are frequently overlooked or misunderstood. These symptoms are also confused with other health issues, resulting in late detection and correct diagnosis of the disease. The severity of ovarian cancer may be exacerbated by late identification and therapy.
Epithelial Ovarian Cancer Drugs Market Opportunities
The expiration of existing companies’ patents can be a boon to new entrants into the market. Adopting innovative combination medicines for treatment is a key driver of the expansion of the ovarian cancer drug market. Government and private-sector funding for research and development are a bonus for the market. Hence, all these factors act as market opportunities.
Download Sample Brochure @ https://www.datamintelligence.com/download-sample/epithelial-ovarian-cancer-drugs-market
COVID-19 Impact Analysis
The market for global epithelial ovarian cancer drugs was expected to be down due to hurdles in the production and sales segments due to the covid-19 pandemic epidemic. Since the epidemic, all manufacturing companies have shut down except for masks, sanitizers, and ventilators. As a result, fewer drugs were manufactured during the outbreak than in prior years.
Recent Developments in the Industry:
On November 29th, 2021, the US Food and Drug Administration approved Cytalux (pafolacianine). The medicine is designed to help doctors detect more ovarian cancer tissue after surgery, which is notoriously difficult to detect. In adult patients with ovarian cancer, Cytalux is utilized to aid in the detection of malignant tumors during surgery. The drug is a diagnostic agent administered via intravenous injection before surgery.
As per the research analysis, the epithelial ovarian cancer drugs are segmented by drug type into Carboplatin-taxon, Gemcitabine-Cisplatin, Bevacizumab, PARP inhibitors, and Others. Based on distribution channels, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others.
On the basis of drug type, the Gemcitabine-Cisplatin segment is estimated to grow at the highest market value during the forecast period (2022-2029). The drug type segment accounted for the largest market share of the global epithelial ovarian cancer drugs market in 2020. The combination of gemcitabine and cisplatin chemotherapy for recurrent ovarian cancer has recently been proved to be an effective treatment. However, most good responses were seen in patients who were either platinum-sensitive or had long platinum-free periods. New drugs and combinations are required to improve current ovarian cancer therapy outcomes. Gemcitabine is a new drug with a favorable safety profile and promising performance as a single agent in treating platinum-resistant ovarian cancer.
According to the report the market is divided into North America, South America, Europe, Asia-Pacific, and Middle East.
North America Epithelial Ovarian Cancer Drugs Market:
North America dominates the market as the United States and Canada have well-structured and developed healthcare systems. The North America epithelial ovarian cancer drugs market size was valued at USD billion in 2021, it is projected to reach USD billion by 2029, with growth at a CAGR of % over the forecast period 2022-2029. The presence of a well-developed healthcare system, a high level of acceptance of novel chemotherapy and radiation therapy methods by medical practitioners, total availability of advanced technological tools, FDA approval of new drugs, and many organizations engaged in cancer vaccine R&D.
Asia-Pacific Epithelial Ovarian Cancer Drugs Market:
The Asia-Pacific epithelial ovarian cancer drugs market size was valued at USD billion in 2021, it is projected to reach USD billion by 2029, with growth at a CAGR of % over the forecast period 2022-2029.
The major players are adopting several growth strategies such as acquisitions, product pipelines, and collaborations, contributing to the growth of the epithelial ovarian cancer drugs market globally.
Epithelial Ovarian Cancer Drugs Market Major Companies:
Some of the key players which are contributing to the growth of the market include GlaxoSmithKline plc, AstraZeneca, Roche, Boehringer Ingelheim GmbH, Millennium Pharmaceuticals, Inc, Amgen, Inc., ImmunoGen, Inc., Pharmacyclics, Inc., Bayer AG, Oasmia Pharmaceutical AB, and others.
Make an Inquiry before buying the full report @ https://www.datamintelligence.com/enquiry/epithelial-ovarian-cancer-drugs-market
Additional Benefits Post Purchase:
1) Unlimited Analyst support for a period of 1 year.
2) Any query with regards to the scope offered will be addressed within 24- 48 hours.
3) An excel sheet with market numbers will be provided separately.
The Full Report has the below insights
The report offers a comprehensive evaluation of the market in terms of Market Value (US$) and Y-o-Y Growth Rates (%). It does so via in-depth qualitative insights, historical data (2020-2021), and verifiable projections about market size during the forecast period (2022-2029).
Visualize the composition of the global epithelial ovarian cancer drugs market segmentation by therapy type, end-user, and country highlighting the key commercial assets and players.
By Drug Type: Carboplatin-taxon, Gemcitabine-Cisplatin, Bevacizumab, PARP inhibitors, and Others
By Distribution channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others
By Region: North America, South America, Europe, Asia-Pacific, and Middle East
Identify commercial opportunities in the global epithelial ovarian cancer drugs market by analyzing trends and co-development deals.
The report also covers data insights on various industry forces such as porter’s five forces, regulations in each country, pipeline analysis, and pricing analysis.
Excel data sheet with thousands of data points global epithelial ovarian cancer drugs market-level 4/5 segmentation.
PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
Product mapping in excel for the key product of all major market players
The report will provide access to approximately 50+ market data tables, 40+ figures, and close to 180 pages.
Company Name: DataM Intelligence
Contact Person: Sai
Email: Send Email
Phone: +1 877 441 4866
Country: United States